{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:25:27Z","timestamp":1787117127784,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Head and neck squamous cell carcinoma (HNSCC) faces challenges with limited immune checkpoint inhibitors (ICIs) efficacy. This study identifies NLRX1, highly expressed in HNSCC tumor cells, as a key driver of immune evasion and ICIs\u2019 resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study investigated the role of NLRX1 in HNSCC immune evasion and ICIs resistance. We performed retrospective analyses on patient cohorts to correlate NLRX1 expression with clinical outcomes. Bioinformatic analyses and immunofluorescence staining of human HNSCC tissues were employed to assess associations between immune cell infiltration, gene expression correlations and PD-L1 levels on antigen-presenting cells (APCs).\n                      <jats:italic>In vitro<\/jats:italic>\n                      experiments were conducted to investigate the regulatory role of NLRX1 on cell proliferation and gene expression profiling by overexpressing or knocking down NLRX1.\n                      <jats:italic>In vivo<\/jats:italic>\n                      studies of subcutaneous tumor models in both immunodeficient and immunocompetent mice were utilized to assess the function of NLRX1 on tumor progression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The expression NLRX1 is correlated with unfavorable patient outcomes. NLRX1 promotes tumor progression by modulating the immune microenvironment, not directly affecting tumor cell proliferation. Mechanistically, NLRX1 suppresses the type I interferon (IFN-I) pathway by inhibiting STING expression in HNSCC. Notably, tumor cell-intrinsic NLRX1 negatively correlates with PD-L1 expression on APCs in HNSCC.\n                      <jats:italic>In vivo<\/jats:italic>\n                      , NLRX1 knockdown activated STING-IFN-I signaling, upregulated APC PD-L1, suppressed tumor growth, and significantly boosted anti-PD-L1 therapy in murine tumor models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NLRX1 mediates immune evasion in HNSCC by downregulating STING protein abundance, suppressing the IFN-I pathway, and decreasing PD-L1 expression of APCs. Targeting NLRX1 offers a promising strategy to overcome ICI resistance and improve immunotherapeutic efficacy in HNSCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1890178","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:39:52Z","timestamp":1787114392000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["NLRX1 contributes to immunotherapeutic resistance of head and neck squamous cell carcinoma by suppressing type I interferon pathway"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuqi","family":"Wu","sequence":"first","affiliation":[{"name":"State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Jiang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Pan","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianming","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Luo","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2018.12.006","article-title":"Immunotherapy for head and neck cancer","volume":"33","author":"Sim","year":"2019","journal-title":"Hematology\/Oncology Clinics North America"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12380","article-title":"Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity","volume":"162","author":"Ramsay","year":"2013","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-023-02912-2","article-title":"Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway","volume":"43","author":"Luo","year":"2024","journal-title":"Oncogene"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1158\/1078-0432.ccr-19-1351","article-title":"Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti\u2013PD-1 resistance in head and neck cancer","volume":"26","author":"Zhou","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-025-01068-3","article-title":"Trends in immunotherapy for oral squamous cell carcinoma","volume":"48","author":"Xue","year":"2025","journal-title":"Cell Oncol (Dordrecht Netherlands)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3892\/ijo.2022.5378","article-title":"Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer (review)","volume":"61","author":"Affolter","year":"2022","journal-title":"Int J Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/jci120803","article-title":"Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade\u2013mediated tumor regression","volume":"128","author":"Lin","year":"2018","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/jci96061","article-title":"PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression","volume":"128","author":"Tang","year":"2018","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nri3790","article-title":"Clinical blockade of PD1 and LAG3--potential mechanisms of action","volume":"15","author":"Nguyen","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2016.08.003","article-title":"Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer","volume":"61","author":"Lei","year":"2016","journal-title":"Oral Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800129","article-title":"IFNAR1 controls autocrine type I IFN regulation of PD-L1 expression in myeloid-derived suppressor cells","volume":"201","author":"Xiao","year":"2018","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nature08476","article-title":"STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity","volume":"461","author":"Ishikawa","year":"2009","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1038\/s41467-023-39920-5","article-title":"ARIH1 activates STING-mediated T-cell activation and sensitizes tumors to immune checkpoint blockade","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.07.020","article-title":"STK11\/LKB1-deficient phenotype rather than mutation diminishes immunotherapy efficacy and represents STING\/type I interferon\/CD8(+) T-cell dysfunction in NSCLC","volume":"18","author":"Li","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1016\/j.cell.2024.04.025","article-title":"ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity","volume":"187","author":"Maxwell","year":"2024","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-2807","article-title":"Mitigating SOX2-potentiated immune escape of head and neck squamous cell carcinoma with a STING-inducing nanosatellite vaccine","volume":"24","author":"Tan","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2016.03.001","article-title":"NLRX1 sequesters STING to negatively regulate the interferon response, thereby facilitating the replication of HIV-1 and DNA viruses","volume":"19","author":"Guo","year":"2016","journal-title":"Cell Host Microbe"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/jci129497","article-title":"HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING","volume":"130","author":"Luo","year":"2020","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nature06501","article-title":"NLRX1 is a regulator of mitochondrial antiviral immunity","volume":"451","author":"Moore","year":"2008","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12986","article-title":"NLRX1\/FUNDC1\/NIPSNAP1-2 axis regulates mitophagy and alleviates intestinal ischaemia\/reperfusion injury","volume":"54","author":"Li","year":"2021","journal-title":"Cell Proliferation"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2023.100635","article-title":"NLRX1: Versatile functions of a mitochondrial NLR protein that controls mitophagy","volume":"47","author":"Bi","year":"2024","journal-title":"Biomed J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00849-x","article-title":"The NLR gene family: From discovery to present day","volume":"23","author":"Chou","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet (London England)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.09.026","article-title":"PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders","volume":"32","author":"Lee","year":"2024","journal-title":"Mol Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/s41419-020-03140-2","article-title":"PD-L1 degradation pathway and immunotherapy for cancer","volume":"11","author":"Gou","year":"2020","journal-title":"Cell Death Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1581313","article-title":"Mystery machine: The complex roles of NLRX1 in viral infection","volume":"16","author":"Woolls","year":"2025","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16331","article-title":"The functions of autophagy at the tumour-immune interface","volume":"25","author":"Luo","year":"2021","journal-title":"J Cell Mol Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.53","article-title":"Targeting autophagy in cancer","volume":"17","author":"Levy","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41421-020-0141-7","article-title":"Lysosome biology in autophagy","volume":"6","author":"Yim","year":"2020","journal-title":"Cell Discov"},{"key":"B36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.taap.2018.02.007","article-title":"Activation of NLRX1-mediated autophagy accelerates the ototoxic potential of cisplatin in auditory cells","volume":"343","author":"Yin","year":"2018","journal-title":"Toxicol Appl Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.03.025","article-title":"The mitochondrial proteins NLRX1 and TUFM form a complex that regulates type I interferon and autophagy","volume":"36","author":"Lei","year":"2012","journal-title":"Immunity"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1890178\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:39:57Z","timestamp":1787114397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1890178\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2026.1890178"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1890178","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1890178"}}